Trevena’s Chronic Pain Therapy Granted U.S. Patent

Trevena’s Chronic Pain Therapy Granted U.S. Patent

Trevena, Inc. has been granted a U.S. patent for TRV734, its investigational treatment for acute and chronic moderate-to-severe pain, as well as compositions comprising TRV734, and methods of using TRV734. The U.S. Patent and Trademark Office (USPTO) awarded U.S. Patent No. 9,044,469, and the company expects to hold full patent coverage for TRV734 until at least 2032.

Trevena is focused on researching and developing biased ligands able to target the G protein coupled receptors (GPCRs), and TRV734 is expected to treat patients with severe and chronic pain. The USPTO granted the company a patent entitled “Opioid Receptor Ligands and Methods of Using and Making Same,” as the company is currently studying TRV734 in a phase 1 clinical trial.

“This patent provides long-term protection in the United States for the TRV734 molecule and its use in treating pain,” stated the CEO of Trevena, Maxine Gowen, PhD. “With this issued U.S. patent, and corresponding patent applications pending in key international markets, we are well positioned to establish a comprehensive and global intellectual property estate for this important asset.

TRV734 is expected to improve analgesia and reduce on-target gastrointestinal and central nervous system adverse effects with an innovative mode of action at the mu-opioid receptor. The investigational oral treatment is similar to the company’s intravenous treatment for the same indication, as it is a biased ligand at the mu-opioid receptor, activating the G protein pathway, related to analgesia, but preventing the activation of the mu-opioid beta-arrestin pathway.

“We now have secured composition of matter patent protection in the U.S. for all three of our clinical stage compounds – TRV130, TRV027 and TRV734,” noted Gowen about the company’s portfolio of investigational drugs. The company currently holds three patented compounds, as well as a fourth one, aiming to address different conditions, which target GPCRs using Trevena’s proprietary product platform.

Trevena is focused on four biased ligand product candidates, including TRV130 an investigational treatment for treat moderate to severe acute pain intravenously, being studied in a phase 2b clinical trial, in addition to TRV734, which is meant to treat the same indication orally. In addition, TRV027 is a potential treatment for acute heart failure that is being examined in a phase 2b clinical trial, and TRV250 is in preclinical studies to treat refractory migraine and other CNS disorders.